M. Asanuma, I. Miyazaki, F. Díaz-Corrales
Feb 1, 2010
Citations
7
Influential Citations
100
Citations
Quality indicators
Journal
Annals of Neurology
Abstract
Recent double‐blind, controlled trials in Japan showed that the antiepileptic agent zonisamide (ZNS) improves the cardinal symptoms of Parkinson's disease. Glutathione (GSH) exerts antioxidative activity through quenching reactive oxygen species and dopamine quinone. GSH depletion within dopaminergic neurons impairs mitochondrial complex I activity, followed by age‐dependent nigrostriatal neurodegeneration. This study examined changes in GSH and GSH synthesis‐related molecules, and the neuroprotective effects of ZNS on dopaminergic neurodegeneration using 6‐hydroxydopamine–injected hemiparkinsonian mice brain and cultured neurons or astrocytes.